Arta Medica (May 2024)
NT-proBNP AN IMPORTANT MARKER IN THE DIAGNOSTIC ALGORITHM IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION AND HEART FAILURE
Abstract
Objectives. Patients with atrial fibrillation have an increased risk of heart failure as well as ischemic stroke. It is very important to monitor the plasma level of the natriuretic hormone NT-proBNP, which has been crystallized as the main biomarker that signals the presence of heart failure, especially in the early stages. The aim of the work consists in the clinical-diagnostic estimation of the NT-proBNP biomarker in patients with non-valvular atrial fibrillation and heart failure. Materials and methods. In the study were included 40 patients with non-valvular atrial fibrillation, hospitalized in the Cardiology department of the Municipal Clinical Hospital ”Sfânta Treime”, between December 2022 and June 2023. The patients included in the research met the criteria for inclusion in the study (the patient's agreement with the signing of the informed consent, age, patients with permanent and persistent non-valvular atrial fibrillation treated with Warfarin). Results and discussions. The study includes patients aged between 50 and 90 years with an average age of 66.98±1.29, the female gender including 42.5% (17 people), and the male gender – 57.5% (23 people). The average weight for men is 91.08 kg and for women – 91.35 kg. The average values of NT-proBNP at hospitalization are 3349.965±661.23 pg/ml and after one month of treatment – 2629.681±733.3076 pg/ml. Conclusions. According to the results obtained, we can confirm that the NT-proBNP marker is a very important, fast (15 minutes) and reliable test. The serum level of this marker increases the most in the case of heart failure, which is diagnosed in all patients in our study with permanent and persistent non-valvular AF.
